Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Alumis shares climb after its psoriasis drug met all late-stage trial goals, showing strong skin clearance, fast results, and ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.

Findings showed 64.7% of icotrokinra-treated patients achieved IGA scores 0/1 and 49.6% achieved PASI 90 compared with 8.3% and 4.4% of those on placebo, respectively. Topline results were announced ...

Alumis (ALMS) shares climbed nearly 150% on Tuesday after the autoimmune disease drug developer said its lead candidate, ...

A real world systematic review and meta-analysis found tildrakizumab improved plaque psoriasis severity and quality of life ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

Alumis said on Tuesday its experimental drug to treat a common skin disease met the main goal in two late-stage studies, offering hope for a new oral treatment option that affects millions of ...

Psoriasis treatments have been a staple of TV advertising for nearly 50 years. That’s because the skin disease is relatively widespread throughout the United States. Roughly 80 to 90 percent of ...

What Is the Auspitz Sign? Auspitz sign is a distinctive mark seen when a skin plaque has been removed. Plaques (also called scales) are common in plaque psoriasis, but people with Darier′s disease and ...

Alisha Bridges, 36, knows what it feels like to be treated differently because of how she looks. Since elementary school, Alisha has struggled with severe plaque psoriasis—a condition which causes ...